5 Under-$10 Stocks Set to Trade Higher in November
This company said today that the FDA Anesthetic and Analgesic Drug Products Advisory Committee, or AADPAC, will review its New Drug Application, or NDA, for Zohydro ER -- hydrocodone bitartrate extended-release capsules -- on Dec. 7, 2012. This news could provide a catalyst for the stock to move substantially higher into that review date.
If you take a look at the chart for Zogenix, you'll notice that the stock is bouncing strongly here right off its 200-day moving average of $2.27 a share with strong upside volume flows. Volume so far today has already hit over 640,000 shares, which is quickly approaching its three-month average action of 645,621 shares. This action is also moving ZGNX within range of challenging its 50-day moving average of $2.61 a share.
Market players should now look for long-biased trades in ZGNX as long as it's trending above its 200-day at $2.27, and then once it clears its 50-day at $2.61 a share with strong upside volume flows. I would consider any upside volume day that registers near or above 645,621 shares as bullish. If ZGNX can trigger that move, then this stock will set up to re-test or possibly take out its next significant overhead resistance levels at $2.90 to $3.10 a share, or possibly even $3.30 a share. Any high-volume move above $3.30 a share would then put $3.90 into focus for ZGNX.
Traders can look to buy ZGNX off any weakness and then simply use a stop that sits just below its 200-day moving average of $2.27 a share. One could also buy off strength once ZGNX takes out its 50-day at $2.61 and then simply use the same stop just below its 200-day.
VASCO Data Security InternationalSelect the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV